Compare NMTC & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMTC | AYTU |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 27.4M |
| IPO Year | 2010 | 2015 |
| Metric | NMTC | AYTU |
|---|---|---|
| Price | $3.24 | $2.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $11.90 | $9.33 |
| AVG Volume (30 Days) | 32.0K | ★ 40.3K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.43 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $9,097,692.00 | ★ $27,632,080.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $31.90 | $43.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 163.47 | ★ 277.47 |
| 52 Week Low | $0.55 | $1.65 |
| 52 Week High | $5.40 | $3.07 |
| Indicator | NMTC | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 38.62 | 42.64 |
| Support Level | $0.69 | $2.17 |
| Resistance Level | $4.87 | $2.30 |
| Average True Range (ATR) | 0.25 | 0.10 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 17.02 | 41.94 |
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.